Lishengpharma(SZ:002393) Zheng Quan Shi Bao Wang·2025-07-15 09:22Core Viewpoint - Lisheng Pharmaceutical (002393) is expected to achieve a significant increase in net profit for the first half of 2025, driven by market expansion and product sales growth despite price reductions [1][2] Group 1: Financial Performance - The company forecasts a net profit of 330 million to 355 million yuan for the first half of 2025, representing a year-on-year growth of 222.42% to 246.85% [1] - The positive performance is attributed to overcoming product price reductions and actively expanding market presence, along with the beneficial impact of Tian Shili Group's dividends [1] Group 2: Product Development and Approvals - Lisheng Pharmaceutical has received approval from the National Medical Products Administration for two specifications of Perindopril Amlodipine tablets, marking it as the second and fourth company in China to obtain such approvals [1] - The approved Perindopril Amlodipine tablets will enhance the company's product portfolio and assist in expanding its business scope [1] - Since 2020, the company has made significant progress in new product development, with multiple drugs achieving breakthroughs, including 11 generic products receiving drug registration certificates and 22 products passing consistency evaluations [2] - The approval of Arginine Perindopril active pharmaceutical ingredient in November 2024 is a key milestone in the company's "raw material + formulation" strategy, indicating a comprehensive breakthrough in the cardiovascular treatment field [2]